Holmes v. Comm'r
This text of 2012 T.C. Memo. 251 (Holmes v. Comm'r) is published on Counsel Stack Legal Research, covering United States Tax Court primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.
Opinion
Decision will be entered under
P sold shares of M at a gain but failed to report that gain, claiming that he is entitled to defer recognizing that gain because a substantial portion of that gain would have qualified for deferral under
*252
HALPERN,
| 2000 | $139,967 | $27,993 | $33,060 |
| 2001 | 116,466 | 23,293 | -0- |
| 2002 | 1217,289 | 43,458 | -0- |
| 2003 | 184,335 | 36,867 | -0- |
| 2004 | 37,368 | 7,474 | -0- |
| 2004 | 37,368 | 7,474 | -0- |
1On brief, petitioner and respondent set forth $271,289 and $217,789, respectively, as the disputed 2002 deficiency in tax. Neither amount corresponds to the determination in the notice. We cannot determine whether those amounts are typographical errors, and neither party explains the numerical discrepancy. Since we decide herein that petitioner did underpay his tax for 2002, we leave it to the parties to resolve the aforementioned discrepancy and related adjustments in their computation(s) under
By amended answer, respondent asserted, for 2000, 2001, 2002, 2003, and 2004 (years in issue),
Free access — add to your briefcase to read the full text and ask questions with AI
Decision will be entered under
P sold shares of M at a gain but failed to report that gain, claiming that he is entitled to defer recognizing that gain because a substantial portion of that gain would have qualified for deferral under
*252
HALPERN,
| 2000 | $139,967 | $27,993 | $33,060 |
| 2001 | 116,466 | 23,293 | -0- |
| 2002 | 1217,289 | 43,458 | -0- |
| 2003 | 184,335 | 36,867 | -0- |
| 2004 | 37,368 | 7,474 | -0- |
| 2004 | 37,368 | 7,474 | -0- |
1On brief, petitioner and respondent set forth $271,289 and $217,789, respectively, as the disputed 2002 deficiency in tax. Neither amount corresponds to the determination in the notice. We cannot determine whether those amounts are typographical errors, and neither party explains the numerical discrepancy. Since we decide herein that petitioner did underpay his tax for 2002, we leave it to the parties to resolve the aforementioned discrepancy and related adjustments in their computation(s) under
By amended answer, respondent asserted, for 2000, 2001, 2002, 2003, and 2004 (years in issue),
*254 Taking into account petitioner's concessions, 3 the issues for decision are whether petitioner: (1) should have included in income capital gains of $498,000, $408,662, $1,097,166, $1,012,702, and $29,425 for 2000, 2001, 2002, 2003, and 2004, respectively, (2) is entitled to capital loss deductions for 2002-04, (3) is liable for the
Some facts are stipulated and are so found. The stipulation of facts, with accompanying exhibits, is incorporated herein by this reference.
At the time he filed the petition, petitioner lived in California.
Petitioner is a medical doctor specializing in pediatric craniofacial surgery. At the time of trial, he was employed as Associate Chief of Craniofacial Surgical Services at Children's Hospital and Health Center in San Diego, California. He received a bachelor *254 of arts degree and a medical degree from Boston University.
In May 1997, petitioner, Christopher Calhoun, and Stefan Lemperle cofounded MacroPore, Inc. (MacroPore), a Delaware C corporation. MacroPore initially engaged in the development, manufacture, and marketing of bioresorbable surgical implants; its central focus later became the development of regenerative therapies. 4
*256 On May 20, 1997, petitioner acquired 1 million shares of MacroPore stock at their original issue for 1 cent per share. He held those shares in a brokerage account with Charles Schwab & Co., Inc. (Charles Schwab).
In August 2000, MacroPore made an initial public offering of stock and was quoted on the Neuer Markt of the Frankfurt Stock Exchange in Germany. The stock later traded on the NASDAQ Capital Market and then on the NASDAQ Global Market.
In 2000, petitioner cofounded LeonardoMD, Inc. (LeonardoMD), a Delaware C corporation. LeonardoMD provides on demand physician practice management software delivered over *255 the Internet. In 2005, petitioner became the corporation's chief executive officer, and later he became its president.
In each year in issue, petitioner sold some of his shares of MacroPore. Between June 20, 2000, and June 10, 2004, he sold a total of 972,500 shares, *257 realizing $3,055,680 in total proceeds. 5 Between January 4, 2002, and July 27, 2004, he purchased shares of LeonardoMD stock in 36 separate transactions. 6
In late 2000, petitioner spoke with Mr. Calhoun "about selling the MacroPore stock and putting it [the proceeds] into the Leonardo company". Mr. Calhoun told him about an article he had read concerning a tax provision that permits taxpayers to roll *256 over gain from a startup company "into another start-up company and then defer that tax until the profit from the second investment." He said that petitioner "should look into it."
Mr. Calhoun is neither a tax professional nor a financial adviser and did not provide to petitioner a written financial opinion. Petitioner did not seek advice from other individuals as to the provision's procedures or requirements, 7 and there is no evidence that he even read the provision.
Petitioner hired Mashallah Afshar, an enrolled agent, to prepare his individual Federal income tax return for each year in issue.
Petitioner untimely filed his 2000 Form 1040, U.S. Individual Income Tax Return. He reported a capital gain of $2,069, 8*257 total tax of $2,093, an estimated tax payment of zero, Federal income tax withheld of $4,911, and an overpayment of $2,818, which he applied to his 2001 estimated tax. Petitioner did not attach to the Form 1040 a Schedule D, Capital Gains and Losses, and did not report that year's MacroPore stock sale.
Petitioner timely filed his 2001 Form 1040. He reported zero capital gain, total tax of $8,280, estimated tax payments of $2,819, Federal income tax withheld of $466, and a tax liability of $4,995. Petitioner did not attach to the Form 1040 a Schedule D and did not report that year's MacroPore stock sales.
Petitioner timely filed his 2002 Form 1040. He reported a capital loss deduction of $3,000, total tax of $273, an estimated tax payment of zero, Federal income tax withheld of $3, and a tax liability of $270. The attached Schedule D reported the following transaction: "Charles Schwab Stock Trsdes [sic]", *259 involving unidentified stock acquired on various dates at a cost or other *258 basis of $512,500 and sold on various dates at $477,050, generating a net long-term capital loss of $35,450.
Petitioner timely filed his 2003 Form 1040. He reported a capital loss deduction of $3,000, total tax of $9,970, an estimated tax payment of zero, Federal income tax withheld of $9,627, and a tax liability of $343. The attached Schedule D reported a $35,450 long-term capital loss carryover from 2002 but did not report that year's MacroPore stock sales.
Petitioner timely filed his 2004 Form 1040. He reported capital gain of $3,405, total tax of $162,932, an estimated tax payment of zero, Federal income tax withheld of $85,466, and a tax liability of $77,466. The attached Schedule D reported the following transaction: the sale of "MacroPore Biosurgery", acquired on September 4, 1992, at a cost or other basis of $37,500 and sold on June 4, 2004, at $29,500, generating a long-term capital loss of $8,000. That long-term capital loss was offset by two other transactions reported on the Schedule D, "Janus Growth & Income" and "Janus Flexible Income", from which a total of $43,855 of long-term capital gain was reported. Part of that long-term capital gain remaining after the offset was *259 then offset by a long-term capital loss carryover of $32,450, resulting in a net long-term capital gain of $3,405.
In 2006, respondent initiated an examination of petitioner's 2003 income tax return, later expanding the examination to include his 2000-02 and 2004-05 tax returns. 9 Respondent assigned Revenue Agent Lawrence Lee to the examination. On February 16, 2006, petitioner executed a Form 2848, Power of Attorney and Declaration of Representative, authorizing Mr. Afshar to represent him before the IRS with respect to tax years 2002, 2003, and 2004.
Early in the examination, Revenue Agent Lee discovered that petitioner had failed to report $568,187 from MacroPore stock sales on his 2003 tax return. On April 24, 2006, Revenue Agent Lee met with Mr. Afshar, and, during their conversation, Revenue Agent Lee identified petitioner as the founder of MacroPore. Mr. Afshar denied that petitioner was the corporation's founder, stating that he had confused petitioner with another Children's Hospital *260 employee who bore the same name.
As the examination progressed, Revenue Agent Lee asked Mr. Afshar about petitioner's MacroPore stock basis. Mr. Afshar refused to answer, telling him that *261 he would only discuss the stock sale with Revenue Agent Lee's group manager, Supervisory Internal Revenue Agent Hassan Mahamoud.
At a meeting of Revenue Agent Lee, petitioner, Agent Mahamoud, and Mr. Afshar, Revenue Agent Lee asked why petitioner had failed to report the MacroPore sales on his tax return. Mr. Afshar replied that "there were no gains involved and that's why nothing was reported." After the meeting, Mr. Afshar sent to Agent Mahamoud a letter dated July 2, 2006, which stated in part: "Please find extra Doc. that I was able to find." The attached document, a spreadsheet, indicates various purchases of MacroPore stock in 1999 and 2000 at costs ranging between $4.25 and $5 per share. Petitioner prepared the spreadsheet after the IRS had initiated the examination. He prepared it knowing that the information it contained was inaccurate and that Mr. Afshar intended to present the spreadsheet to Agent Mahamoud. Petitioner understood that the spreadsheet would be submitted to the IRS for the *261 purpose of evading tax.
At some point, Mr. Afshar invited Agent Mahamoud to lunch to discuss the pending audit. At the lunch meeting, Mr. Afshar offered to pay for Agent Mahamoud's lunch and offered him a framed painting (or drawing or lithograph) of a Mideastern design with Islamic religious sayings written in Arabic. Islam is *262 the common religion of Mr. Afshar and Agent Mahamoud. Agent Mahamoud declined both offers.
In 2007, through a third-party inquiry of Cytori, MacroPore's successor, Revenue Agent Lee learned that "Dr. Holmes got a million shares [of MacroPore] for a penny each." He scheduled an October 17, 2007, interview with petitioner to discuss that newly discovered information. On the morning of the interview, however, Mr. Afshar canceled the meeting, an employee in his office stating that petitioner "was busy with his surgery schedule".
In December 2007, petitioner consulted attorneys at the Waage Law Firm regarding tax years 2003 and 2004. They advised him of the statutory requirements to qualify for a deferral of gain under
*263 On behalf of petitioner, Mr. Martin submitted to respondent a "Revenue Ruling Submission Application for Relief under
Respondent sent to petitioner a letter dated October 24, 2008, denying his
In the notice, respondent, among other things, made adjustments to petitioner's reported income reflecting petitioner's failure to report gain from sales of MacroPore stock in 2000-04. Respondent also made adjustments disallowing the following deductions: the $35,450 capital loss claimed for 2002; the related $3,000 capital loss claimed for 2002 and the $3,000 capital loss carryover claimed for 2003; the $8,000 capital loss claimed for 2004; and the $32,450 capital loss carryover claimed for 2004. As noted above, respondent also determined a
Respondent contends that petitioner was required to report on his 2000, 2001, 2002, 2003, and 2004 income tax returns gain from sales of MacroPore stock in the amounts of $498,000, $408,662, $1,097,166, $1,012,702, and $29,425, respectively.
*265 Petitioner does not dispute that he realized gain in those amounts or that he failed to report that gain on his tax returns for those years. Instead, he argues that he is entitled to defer recognition of that gain because (1) a substantial portion of the gain from those sales would have qualified for deferral under
Petitioner bears the burden of proof.
The amount of gain from the sale or other disposition of property is the excess of the amount realized therefrom over the adjusted basis of the property.
Generally, a taxpayer must recognize the entire amount of gain realized from the sale or exchange of property.
"Qualified small business stock" has the same meaning given to it by
In relevant part, a "qualified small business" is any domestic C corporation if: (1) its aggregate gross assets did not exceed $50 million before the issuance, and (2) its aggregate gross assets immediately after the issuance (taking into account amounts received in the issuance) do not exceed $50 million.
As relevant herein, to elect the application of (a) reporting the entire gain from the sale of * * * [qualified small business stock] on Schedule D, Capital Gains and Losses, * * * (b) writing " *268 (c) entering the amount of the gain deferred under
The *268 parties' disagreement centers around whether: (1) petitioner's shares of LeonardoMD and MacroPore stock constituted "qualified small business stock" as defined under
The parties agree that the LeonardoMD stock purchased between January 4, 2002, and July 27, 2004, satisfies some of the aforementioned qualified small business stock requirements but dispute whether: (1) petitioner acquired the stock at its original issue in exchange for money, (2) LeonardoMD was a qualified small business because its aggregate gross assets before and immediately after the issuance did not exceed $50 million, and (3) during substantially all of petitioner's *269 holding period for the stock, LeonardoMD used at least 80% of its assets in the active conduct of one or *269 more qualified trades or businesses.
Petitioner has proffered no evidence beyond his own uncorroborated testimony to establish that he acquired LeonardoMD stock at its original issue. "Original issue" is defined as the "first issue of securities of a particular type or series." Black's Law Dictionary 908 (9th ed. 2009). At trial, petitioner first testified that he purchased shares of LeonardoMD stock over time "from the president and his—up till 2005. I purchased them from the president and his accountant at the company, at LeonardoMD." That testimony appears to contradict his later testimony that he invested directly in the company and never bought stock from someone else. In any event, petitioner offered no documentary evidence, such as stock certificates or book entries from the corporation, indicating from whom he acquired the stock on each of the 36 stipulated purchase dates. He further failed to submit evidence showing that on each of those 36 purchase dates, he purchased any of the original issue of that stock type or series. We cannot (and do not) find that petitioner acquired LeonardoMD stock at its original issue; petitioner has failed to carry his burden of proof on that *270 point.
We similarly cannot find that LeonardoMD was a qualified small business on the days on which he purchased its stock. As stated Q: Have the gross assets of LeonardoMD ever exceeded $50 million? A: No.
Petitioner purchased shares of LeonardoMD stock on 36 separate dates between January 4, 2002, and July 27, 2004. Yet he made no attempt to introduce balance sheets or other financial statements showing the amount of cash and property held by the corporation before and immediately after each of those dates or at any time during the corporation's existence.
To lend credence to his purported knowledge of LeonardoMD's finances, petitioner testified that, since taking *271 on executive responsibilities in 2005 (after the years in issue), he has looked at its corporate financial documents. Absent corroborating documentary evidence, we need not, and do not, conclude, solely on *271 the basis of petitioner's self-serving testimony, that LeonardoMD's aggregate gross assets did not exceed $50 million on the days he received its stock.
Finally, petitioner failed to prove that LeonardoMD met the active business requirements of Q: Does [LeonardoMD] have investment assets * * * * A: No investment assets. All of the revenue is used in its business.
Petitioner has failed to prove that the LeonardoMD stock that he purchased between January 4, 2002, and July 27, 2004, constituted qualified small business stock within the meaning of
Under
*273 We note, however, that contrary to petitioner's position that
Because we concluded
We conclude that, for each year in issue, petitioner is not entitled under
A taxpayer must keep records to establish his entitlement to deductions; if he carries a deduction over to a succeeding year, he must keep records to substantiate that amount carried over.
On his 2002 Schedule D, petitioner reported a $35,450 net long-term capital loss, which, because of the
In the petition, petitioner avers nothing with respect to the long-term capital losses, capital loss deductions, and long-term capital loss carryovers.
We accept petitioner's concession as to the 2004 $8,000 long-term capital loss. We interpret petitioner's second statement, about his stock basis, to be that he is entitled to the 2002 capital loss deduction he claimed (and the resulting carryover of that loss to 2003 and 2004) because the stock transactions reported on the 2002 Schedule D did not principally involve the MacroPore stock at issue herein (but some other stock) and thus accurately reported the aggregate bases and resulting long-term capital loss. Irrespective of that statement's truth, petitioner offered no evidence aside from his 2002 tax return to show that he incurred the $35,450 net long-term capital loss during that taxable year and that the loss could be carried over to tax years 2003 and 2004. A taxpayer's returns alone do not substantiate deductions or losses.
Because petitioner failed to adequately substantiate the claimed 2002 $35,450 net long-term capital loss, we find that petitioner is not entitled to any of the disallowed losses.
There is recognized to petitioner capital gain in the amounts of $498,000, $408,662, $1,097,166, $1,012,702, and $29,425 for 2000, 2001, 2002, 2003, and 2004, respectively. Moreover, petitioner is not entitled to a $3,000 capital loss deduction for 2002 and 2003, an $8,000 capital loss deduction for 2004, or a $32,450 net long-term capital loss carryover to 2004. Accordingly, his taxable income is increased on account of those adjustments (and on account of mechanical adjustments with respect to his personal exemption) by $500,800, $411,562, $1,103,166, $1,015,702, and $69,875 for 2000, 2001, 2002, 2003, and 2004, respectively. 15*280
We next determine whether petitioner is liable for a
Respondent has shown by clear and convincing evidence that petitioner underpaid his tax for each year in issue. Petitioner stipulated that he received proceeds in each year in issue from the sale of MacroPore stock and that he failed to include them in his income. He disputes the taxability of the resulting gain, arguing his entitlement to defer its recognition pursuant to
We find that respondent has shown by clear and convincing evidence that petitioner underreported his gross income and, consequently, underpaid his tax, for each year in issue.
The second prong of the fraud test requires the Commissioner to prove that, for each year in issue, at least some portion *282 of the taxpayer's underpayment of tax is due to fraud. Fraud for that purpose is defined as intentional wrongdoing, with the specific purpose of avoiding a tax believed to be owed.
We find that respondent has failed to prove by clear and convincing evidence that petitioner had the specific intent to evade tax when he filed his 2000-04 Federal tax returns. Respondent contends that five indicia of fraud exist: (1) understatement of income, (2) implausible and inconsistent explanations of behavior, (3) failure to cooperate with tax authorities, (4) failure to make estimated payments, and (5) petitioner's education and sophistication. 16 Although *282 respondent has proffered some evidence of fraud, that evidence relates exclusively to petitioner's postfiling actions and does not convince us of his intention to evade tax when he filed his tax return for each year in issue. Respondent must prove by clear and convincing evidence that petitioner *284 intended to evade tax
A pattern of consistent underreporting of income, particularly when accompanied by other circumstances exhibiting an intent to conceal, justifies the inference of fraud.
*283 Petitioner failed to report on each of the subject tax returns substantial amounts of gain from MacroPore stock sales. As a result he underreported his income for each year in issue. We do not find, however, that he did so with the requisite fraudulent intent. Petitioner testified that, from a discussion with Mr. Calhoun in late 2000, he believed that recognition of those gains could be deferred because he sold "stock in one start-up company and invest[ed] that in another * * * start-up company." He further testified that he directed his tax return preparer, Mr. Afshar, to defer those gains on his 2000-04 tax returns and assumed "that he knew how to do that", himself remaining ignorant of, and uninterested in, the statutory and regulatory requirements for so doing. We find that petitioner's actions before he filed the subject returns support a conclusion that, at that time, he believed in good faith that he need not immediately recognize those gains. Respondent did not point to anything in the record attributing petitioner's failure to recognize the full amount of realized gain for each taxable year at issue to his intent *286 to evade his tax liability rather than to his possible negligence and disregard of the applicable statutory and regulatory requirements.
We are not swayed by petitioner's concession that he deferred recognition of the entire amount of gain realized for 2001-04 despite not having reinvested all of the MacroPore sale proceeds for those years in LeonardoMD stock. We have *284 found no evidence that, in so doing, petitioner knew that his reported tax liabilities for those years failed to reflect his true tax liabilities and thereby intended to conceal income and evade tax.
We are, however, suspicious of petitioner's failure to report gain on his 2000 tax return, but suspicious circumstances alone will not sustain a finding of fraud.
*285 We also disagree with respondent that petitioner fraudulently claimed long-term capital losses for 2002 and 2004. Respondent asserts that petitioner fraudulently claimed a $35,450 long-term capital loss from Charles Schwab stock trades in 2002 because he reported on the attached Schedule D inflated stock bases in MacroPore stock. We infer from respondent's contention an assumption that petitioner sold some of his shares of MacroPore stock, in which he held a basis of 1 cent each, in those transactions. As discussed
Respondent failed to offer clear and convincing evidence of petitioner's intent to evade tax in filing the 2004 Schedule D, which reports an $8,000 long-term capital loss from the sale of "MacroPore Biosurgery". Although petitioner concedes it is an "erroneous loss", 17 he asserts that "the entry was made by Petitioner's return preparer, Afshar, and Petitioner had informed Afshar that he sought to defer or roll over gains from the sale of stock in MacroPore and always *286 assumed that Afshar knew how to do that in the preparation of Petitioner's returns." We find unlikely petitioner's ignorance of the erroneousness of the long-term capital loss upon filing the tax return because 2004 is the only year for which he omitted that year's realized MacroPore gain and reported a long-term capital loss from the stock sales. Although asserting the same aforementioned argument for taxable years 2000-03, he did not claim similar long-term capital losses for those years and did not offer an explanation as to that disparate tax reporting. Nevertheless, *289 we are not convinced that he indeed intended, in filing the 2004 tax return, to deceive respondent and avoid his proper tax liability by claiming the erroneous loss. Mindful that it is respondent's burden to prove fraud by clear and convincing evidence, and absent persuasive supporting evidence, we cannot find that petitioner had the requisite fraudulent intent for 2004.
Respondent has failed to prove by clear and convincing evidence that petitioner understated his income for any year in issue with the intent to evade tax.
Respondent next contends that petitioner "(personally or through his representative) offered a series of inconsistent explanations as to why he failed to report his substantial gains from his sales of MacroPore stock", specifically Mr. Afshar's statements that: (1) petitioner held no interests in MacroPore, *287 denying that petitioner founded the corporation, (2) "the deposits into petitioner's Charles Schwab account resulted from transfers" from petitioner's other bank accounts, *290 and (3) "petitioner had no gains as a result of the sales". He argues that, to support the latter statement, petitioner prepared, and Mr. Afshar submitted to Agent Mahamoud, a spreadsheet listing false bases in his shares of MacroPore for the purpose of misleading respondent's agents "into concluding the audit, thereby allowing petitioner to evade tax."
While the law is clear that fraudulent intent must exist at the time the taxpayer files the return,
*288
Respondent next argues that petitioner failed to cooperate with respondent's agents during the examination of his tax returns, an indicium of fraud. He asserts specifically that: (1) petitioner *292 failed to attend scheduled meetings, failed to produce requested records, "and provided vague or inaccurate explanations to justify his improper" tax reporting, (2) Mr. Afshar, petitioner's representative, would communicate only with Agent Mahamoud because he believed that he "could persuade Mr. Mahamoud to accept the false bases for MacroPore" by *289 appealing to their cultural and religious similarities, and (3) Mr. Afshar attempted to influence Agent Mahamoud "into accepting larger false bases by offering him gifts".
We disagree. Respondent furnished no evidence that, in canceling the October 17, 2007, meeting petitioner intended to hinder the audit in hopes of evading tax believed to be owing. When canceling the meeting on behalf of petitioner, Mr. Afshar's employee cited as the reason petitioner's busy surgery schedule. Respondent, although incredulous as to the reason, stating on brief that "the interview was scheduled over a month prior to the interview date", proffered no evidence refuting its truth. We cannot conclude that a sudden claimed change in petitioner's surgery schedule alone evidences an intent to evade tax. To the contrary, petitioner or Mr. Afshar attended other meetings *293 with Revenue Agent Lee and agreed with respondent's request to extend the applicable periods of limitation for assessment for each year in issue so that a more complete audit could be performed.
We do find, however, that petitioner failed to cooperate with respondent's agents by intentionally submitting a false document.
Finally, the record is devoid of evidence indicating that Mr. Afshar's actions towards Agent Mahamoud, while highly inappropriate, were part of petitioner's scheme of tax evasion initiated at the time of filing the subject tax returns. As we have stated above, it seems more likely that Mr. Afshar's actions were a continuation of his attempt at mitigating the tax preparation errors.
*291 We find that, although petitioner failed to cooperate with respondent's agents by intentionally submitting a false document, his failure does not compel the conclusion that he had a fraudulent intent in filing his 2000-04 tax returns.
Respondent contends that petitioner's failure to make adequate estimated tax payments for each year in issue indicates his intention to not pay his correct tax liabilities for those years. Petitioner disagrees, arguing *295 that his "estimated tax payments and withholdings were in amounts adequate to the payment of the tax liability shown to be due on the return". He further asserts that his failure to pay estimated tax in excess of the reported tax liabilities is further evidence of his belief that he "could defer the recognition of gain from the sale of stock in MacroPore by investing the proceeds of the sale in LeonardoMD."
Respondent has offered no evidence and we have found no indication in the record that petitioner knew that his liability for each year in issue required estimated tax payments in excess of those reported.
We find that respondent has failed to prove by clear and convincing evidence that any part of the underpayments of tax required to be shown on petitioner's 2000-04 returns was due to *296 fraud. Accordingly, petitioner is not liable for a
We next consider whether, alternatively, petitioner is liable for a
*293 The Commissioner bears the burden of production.
Petitioner assigns error to respondent's determination of an accuracy-related penalty for each year in issue on the grounds of "(1) negligence or disregard of rules or regulations, (2) a substantial understatement of income tax, or (3) a substantial valuation misstatement." On brief, respondent relies only on the grounds of substantial understatement of income tax and negligence. We construe that as a concession that the other grounds for imposition of the penalty for each year in issue are inapplicable.
Only one accuracy-related penalty may be applied with respect to any given portion of an underpayment, even if that portion is subject to the penalty on more than one of the grounds described in
Respondent has satisfied his burden of production regarding the existence of substantial understatements of income tax for the years in issue. We have for those years sustained respondent's adjustments to petitioner's taxable income in the amounts of $500,800, $411,562, $1,103,166, $1,015,702, and $69,875, respectively. The resulting deficiencies, which in this case equal the understatements, are $139,967, $116,466, $217,289, $184,335, and $37,368, respectively. An incomplete Form 5278, Statement—Income Tax Changes, attached to the notice of deficiency, shows that the amounts of tax required to be shown on petitioner's 2000, 2001, and 2002 Forms 1040 are $142,060, $124,746, *295 and $217,562, respectively. Each understatement of income tax for 2000-02 exceeds the greater of 10% of the tax required *299 to be shown on the tax return or $5,000. While the incomplete Form 5278 is missing the page that would show the amounts required to be shown on petitioner's 2003 and 2004 returns, we think it a fair assumption that those amounts here equal the sum of the deficiency for the year plus the total tax shown on the year's return; viz, $194,305 and $200,300 for 2003 and 2004, respectively.
Accordingly, petitioner is liable for the 20% accuracy-related penalty under
A taxpayer may avoid the
A taxpayer may demonstrate reasonable cause through good faith reliance on the advice of an independent professional, such as a tax adviser, lawyer, or accountant, as to the item's tax treatment.
*297 On brief, petitioner argues that he "ought not to be subject to any accuracy-related penalty" because he "acted in good faith reliance on the advice of a enrolled agent and qualified tax return preparer, and made reasonable and good faith efforts to assess his proper tax liability." He then seems to direct us to his arguments made with respect to satisfaction of
We find that petitioner failed to act with reasonable cause and in good faith with respect to the unreported gain for 2000, 2001, and 2002, and the Schedule D *298 loss for 2002. Petitioner produced no evidence that Mr. Afshar was a competent tax adviser with sufficient expertise to justify his reliance. Petitioner also produced no evidence that he provided to Mr. Afshar pertinent details underlying the disputed tax items. He testified that he provided to Mr. Afshar "pages from Microsoft Money", a computer program used to maintain his income and expenditures, Forms 1099 issued by Charles Schwab listing that year's amount of MacroPore stock sale proceeds, and Charles Schwab account statements reflecting sales of that year's MacroPore stock. In support of his testimony, he produced what appear to be incomplete copies of monthly Charles Schwab account statements 18 for four statement periods in 2001 and five statement periods in 2002. He did not explain the absence of the 2000 account statements or *303 the missing monthly statements for 2001 and 2002.
His failure to explain those absences does not matter, however, because there is no evidence that he actually supplied Mr. Afshar with the documents he did produce or with any other pertinent information with which to properly prepare his tax returns. Petitioner did not call Mr. Afshar as a witness to testify, and "[t]he failure of a party to call such available witnesses that purportedly have *299 knowledge about relevant facts provides sufficient basis to infer that the testimony of such witnesses would not have been favorable to the party."
We further find that petitioner did not fully inform Mr. Afshar of his LeonardoMD stock purchases in 2002, 2003, and 2004, a critical aspect underlying the alleged tax treatment of the MacroPore stock sale proceeds. The above-referenced affidavit states: "In my capacity as tax return preparer for LeonardoMD, I was aware that * * * [petitioner] had reinvested the proceeds of such sales in the stock of LeonardoMD." The affidavit does not state that petitioner supplied him with this information to ensure accurate tax preparation; rather, it *300 implies that he left Mr. Afshar to learn of the LeonardoMD transactions by chance through his role as accountant for LeonardoMD.
In addition, petitioner has not proved that he received or relied upon Mr. Afshar's advice with respect to the tax treatment of the gain and Schedule D loss at issue herein. In order to constitute "advice" under
Petitioner contends that he "made reasonable and good faith efforts to assess his proper tax liability" with respect to the disputed tax items. He, however, *301 produced no evidence in support of that contention, and we find none in the record. Petitioner is highly educated and intelligent and a successful businessman who has cofounded at least two corporations. With respect to the *306 MacroPore sale proceeds, he declined to make inquiries after his discussion with Mr. Calhoun as to the accuracy of Mr. Calhoun's statement concerning their tax treatment. He chose instead to "assume[] that it was true that * * * [he] could— * * * [he] could roll this over". He testified that, on the basis of information from Mr. Calhoun, unfamiliar himself with tax law, he told Mr. Afshar that he wanted to defer recognition of the realized MacroPore gain and assumed that he "knew how to do that." As stated
Petitioner failed to carry his burden of proving that he acted with reasonable cause and in good faith with respect to the unreported gain for 2000, 2001, and2002 and the Schedule D loss for 2002. Accordingly, we find petitioner is liable for the
The Commissioner bears the same burden of production for the
The parties stipulated that petitioner failed to timely file his 2000 Form 1040. Respondent has, therefore, satisfied his burden of production. Petitioner made no argument at trial or on brief that his failure *308 to timely file the return was due to *303 reasonable cause and not willful negligent. We, therefore, hold that petitioner is liable for the
Petitioner is liable for the deficiencies, penalties, and additions to tax as redetermined herein.
Footnotes
1. Unless otherwise stated, section references are to the Internal Revenue Code in effect for the years in issue, and all Rule references are to the Tax Court Rules of Practice and Procedure. We round all amounts to the nearest dollar.
2. On brief, both parties list $163,342 as the
sec. 6663(a) penalty amount for 2002, which differs from that in the amended answer. Since we find petitioner not liable for anysec. 6663(a)↩ penalty, we need not resolve that discrepancy.3. Petitioner concedes that (1) the periods of limitations on assessment provided by
sec. 6501↩ remain open for 2000-04, and that (2) he is not entitled to depreciation deductions of $7,012 and $3,629 that he claimed on Schedules C, Profit or Loss From Business, for 2003 and 2004, respectively.4. At some point, the corporation changed its name to MacroPore Biosurgery, Inc., and then to Cytori Therapeutics, Inc. (Cytori), but we shall continue to refer to it as MacroPore.↩
5. The stipulation is in conflict as to whether the first and last sale dates were as stated or occurred on February 7, 2000, and June 15, 2004, respectively. We do not think that the conflict affects our analysis.↩
6. The parties stipulated the dates of the MacroPore and LeonardoMD stock sales and purchases as well as the amounts of sale proceeds received and amounts paid in each transaction, and we need not set forth those dates and amounts here.↩
7. Petitioner does not claim that the referenced statutory provision is
sec. 1045 , discussedinfra↩ , but we assume that to be the case.8. Because the parties stipulated that petitioner failed to report gain from the sale of MacroPore stock for taxable years 2000-04, we assume that that amount represents capital gain from an unrelated transaction.↩
9. Respondent later closed his examination of tax year 2005 without making any change to petitioner's return because "[n]o stock sales were found in 2005."↩
10. The letter also included a decision as to tax year 2006, but that year is not in dispute and we do not address it.↩
11. Petitioner makes no argument that, pursuant to
sec. 7491(a) , the burden shifts to respondent. In any event, the record establishes that petitioner does not satisfy the preconditions found insec. 7491(a)(2)↩ .12. In 2001, 2002, and 2003, petitioner received more in MacroPore stock sale proceeds than he spent in LeonardoMDstock purchases: for 2001 and 2003, he received $300,162 and $215,602, respectively, more in MacroPore stock sale proceeds. For 2002, he received either $205,416 or $305,416 more in MacroPore stock sale proceeds (the record is unclear as to the exact amount, but it is the fact of the excess, not the amount, that matters).
13. On brief, respondent argues that, contrary to petitioner's assertion, he "never made a request with respondent, formal or otherwise, for extensions of time to make a
section 1045 election[] for his 2000, 2001, and 2002 tax years. It was only in his petition to Tax Court that petitioner requested retroactivesection 1045 deferral" for those tax years. He asserts that, therefore: "It is arguable that the Court lacks jurisdiction in this case over petitioner's request in his petition relating to taxable years 2000, 2001, and 2002". Because we find that, for those taxable years, petitioner is not as a matter of law entitled undersec. 1045↩ to defer gain from the sales of MacroPore stock, we need not address respondent's argument.14. The carryover apparently should have been $32,450 because of the $3,000 capital loss claimed for 2002.
See sec. 1212(b)(2)(A)↩ . The error carried over to 2004.15. As stated
infra sec. III.B. of this report, the record contains an incomplete Form 5278, Statement—Income Tax Changes. We cannot determine, on the basis of that incomplete Form 5278, whether petitioner claimed personal exemptions for 2003 and 2004, which require adjustment. We leave it to the parties to resolve that issue in their computation(s) underRule 155↩ .16. A taxpayer's education and sophistication are not themselves badges of fraud but are merely relevant factors in determining "whether a taxpayer could have formed the intent necessary to be found liable for the fraud penalty."
. Petitioner is highly educated, intelligent, and a successful businessman who has cofounded at least two corporations. We hold him to that standard while evaluating his actions.Wickersham v. Commissioner , T.C. Memo. 1999-276, 1999 WL 632707, at *5↩17. The parties do not dispute that the transaction reported on petitioner's 2004 Schedule D involves the MacroPore stock at issue herein.↩
18. The Charles Schwab account statements list, among other things, trade dates, quantities, and unit prices of various stock and bond fund activities.↩
Related
Cite This Page — Counsel Stack
2012 T.C. Memo. 251, 104 T.C.M. 250, 2012 Tax Ct. Memo LEXIS 250, Counsel Stack Legal Research, https://law.counselstack.com/opinion/holmes-v-commr-tax-2012.